Foghorn Therapeutics Inc (NAS:FHTX)

$ 7.68 0.08 (1.05%) Market Cap: 424.92 Mil Enterprise Value: 174.02 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 52/100

Foghorn Therapeutics Inc. at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023
Foghorn Therapeutics Inc. at Goldman Sachs Healthcare Conference Transcript
Jun 15, 2023
Foghorn Therapeutics Inc. at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Foghorn Therapeutics Inc. at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023
Foghorn Therapeutics Inc. at Cowen Health Care Conference Transcript
Mar 08, 2023
Foghorn Therapeutics Inc. Artificial Intelligence and the Future of Healthcare and Biotech Transcript
Feb 01, 2023
Foghorn Therapeutics Inc. at Bank of America Precision Oncology Conference Transcript
Oct 03, 2022
Foghorn Therapeutics Inc. at Goldman Sachs Global Healthcare Conference Transcript
Jun 13, 2022
Foghorn Therapeutics Inc. at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) Transcript
Jun 02, 2022
Foghorn Therapeutics Inc. at Guggenheim Healthcare Talks: Targeted Protein Degradation Day (Virtual) Transcript
Mar 16, 2022
Foghorn Therapeutics Inc. at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 08, 2021

Foghorn Therapeutics Inc. at Bank of America Precision Oncology Conference Transcript

Oct 03, 2022 / 04:20PM GMT

Release Date Price: $8.25 (-3.85%)

Transcript

Chi Fong

Bank of America - Analyst

Hello. Good day, everyone. Welcome to the BofA Precision Oncology Conference, and our next fireside chat with Foghorn Therapeutics. My name is Chi Fong. I'm one of the biotech EPs here at BofA. I'm pleased to introduce Adrian Gottschalk, CEO from Foghorn Therapeutics. First, I'll turn to Adrian for some quick remarks, and then we can begin our Q&A.

Adrian Gottschalk

Foghorn Therapeutics Inc. - President & CEO

Great. Good afternoon, Chi, and thank you to you and Bank of America for having us on today. Pleasure to be with you and looking forward to our conversation this afternoon. Maybe just a quick brief intro on Foghorn before we jump into the Q&A.

So we're a clinical-stage biotech company. We are focused on treating serious diseases that are caused by dysregulation of gene expression. We've built a very robust platform over the past five to six years that allows us to interrogate this biology in a way that has been inaccessible to others. And I know we'll talk a bit about that today as well.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.